IL258862B - N-[2-(1-Benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperidine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 antagonists for the treatment of neurological diseases - Google Patents
N-[2-(1-Benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperidine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 antagonists for the treatment of neurological diseasesInfo
- Publication number
- IL258862B IL258862B IL258862A IL25886218A IL258862B IL 258862 B IL258862 B IL 258862B IL 258862 A IL258862 A IL 258862A IL 25886218 A IL25886218 A IL 25886218A IL 258862 B IL258862 B IL 258862B
- Authority
- IL
- Israel
- Prior art keywords
- benzylpiperidin
- pyrazin
- piperazine
- antagonists
- ethyl
- Prior art date
Links
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 title 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 title 1
- NTEFDRIAFGEYBB-UHFFFAOYSA-N N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-pyrazin-2-ylpiperazine-1-carboxamide Chemical class C(C1=CC=CC=C1)N1CCC(CC1)CCNC(=O)N1CCN(CC1)C1=NC=CN=C1 NTEFDRIAFGEYBB-UHFFFAOYSA-N 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562252179P | 2015-11-06 | 2015-11-06 | |
| US201662275708P | 2016-01-06 | 2016-01-06 | |
| PCT/US2016/060659 WO2017079641A1 (en) | 2015-11-06 | 2016-11-04 | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL258862A IL258862A (en) | 2018-06-28 |
| IL258862B true IL258862B (en) | 2021-02-28 |
Family
ID=57349137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL258862A IL258862B (en) | 2015-11-06 | 2018-04-23 | N-[2-(1-Benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperidine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 antagonists for the treatment of neurological diseases |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11033539B2 (enExample) |
| EP (1) | EP3371164B1 (enExample) |
| JP (2) | JP6917989B2 (enExample) |
| KR (1) | KR20180073685A (enExample) |
| CN (1) | CN108349936B (enExample) |
| AU (1) | AU2016348524B2 (enExample) |
| BR (1) | BR112018008630A2 (enExample) |
| CA (1) | CA3001873A1 (enExample) |
| CL (1) | CL2018001217A1 (enExample) |
| CO (1) | CO2018004800A2 (enExample) |
| ES (1) | ES2915266T3 (enExample) |
| HK (1) | HK1253029A1 (enExample) |
| IL (1) | IL258862B (enExample) |
| MA (1) | MA43168A (enExample) |
| MX (1) | MX386148B (enExample) |
| MY (1) | MY194461A (enExample) |
| PE (1) | PE20181010A1 (enExample) |
| PH (1) | PH12018500940A1 (enExample) |
| SA (1) | SA518391518B1 (enExample) |
| SG (1) | SG11201803757UA (enExample) |
| TN (1) | TN2018000130A1 (enExample) |
| WO (1) | WO2017079641A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108349944B (zh) | 2015-11-06 | 2021-03-30 | 豪夫迈·罗氏有限公司 | 二氢吲哚-2-酮衍生物 |
| HK1253029A1 (zh) * | 2015-11-06 | 2019-06-06 | Neurocrine Biosciences, Inc. | 作为毒蕈碱性受体4(m4)拮抗剂用於治疗神经系统疾病的n-[2-(1-苄基哌啶-4-基)乙基]-4-(吡嗪-2-基)-哌嗪-1-甲酰胺衍生物及相关化合物 |
| JP2020530451A (ja) | 2017-08-08 | 2020-10-22 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| JP2020537667A (ja) | 2017-10-17 | 2020-12-24 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| CN111491920B (zh) | 2017-10-20 | 2024-01-30 | 范德比尔特大学 | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 |
| US11352344B2 (en) | 2017-10-31 | 2022-06-07 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| WO2019126559A1 (en) | 2017-12-20 | 2019-06-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| CA3090130A1 (en) | 2018-02-02 | 2019-08-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| IL277071B2 (en) | 2018-03-08 | 2024-07-01 | Incyte Corp | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
| WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
| WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
| EP3846806A4 (en) * | 2018-09-04 | 2022-06-08 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine m1 receptor antagonists |
| JP7626722B2 (ja) * | 2019-06-17 | 2025-02-04 | デシフェラ・ファーマシューティカルズ，エルエルシー | アミノピリミジンアミドオートファジー阻害剤およびその使用方法 |
| CA3150906A1 (en) * | 2019-09-17 | 2021-03-25 | Renato T. Skerlj | Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| EP4069367B1 (en) | 2019-12-06 | 2024-05-15 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| CN111072551A (zh) * | 2019-12-30 | 2020-04-28 | 上海睿瓦科技有限公司 | 催化氢化一步法制取哌啶胺的方法 |
| TWI889751B (zh) * | 2020-02-05 | 2025-07-11 | 美商紐羅克里生物科學有限公司 | 蕈毒受體4拮抗劑及使用方法 |
| WO2022156708A1 (en) * | 2021-01-20 | 2022-07-28 | Jacobio Pharmaceuticals Co., Ltd. | Parp7 enzyme inhibitor |
| AU2022289728A1 (en) * | 2021-06-11 | 2023-11-16 | Neuronascent, Inc. | Methods and compositions for lipid formulation of lipophilic small molecule therapies of the heterocyclic type |
| TW202321222A (zh) * | 2021-07-30 | 2023-06-01 | 美商紐羅克里生物科學有限公司 | 蕈毒鹼受體4拮抗劑及使用方法 |
| AU2023382489A1 (en) * | 2022-11-16 | 2025-06-05 | Vyrnwy Therapeutics, Inc. | Inhibitors of tyk2 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993013083A1 (en) * | 1991-12-31 | 1993-07-08 | Fujisawa Pharmaceutical Co., Ltd. | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
| GB9313201D0 (en) * | 1993-06-25 | 1993-08-11 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| US5700801A (en) | 1994-12-23 | 1997-12-23 | Karl Thomae, Gmbh | Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| AU744685B2 (en) * | 1997-11-18 | 2002-02-28 | Teijin Pharma Limited | Cyclic amine derivatives and their use as drugs |
| DE60023878T2 (de) * | 1999-05-18 | 2006-07-20 | Teijin Ltd. | Heilmittel und vorbeugung für mit chemokinen verbundenen erkrankungen |
| ES2215055T3 (es) | 1999-09-22 | 2004-10-01 | Schering Corporation | Antagonistas muscarinicos. |
| AU778173B2 (en) * | 1999-12-08 | 2004-11-18 | Teijin Limited | Cycloamine CCR5 receptor antagonists |
| US6362177B1 (en) * | 2000-05-16 | 2002-03-26 | Teijin Limited | Cyclic amine derivatives and their use as drugs |
| JPWO2003062234A1 (ja) * | 2002-01-23 | 2005-05-19 | 山之内製薬株式会社 | キノキサリン化合物 |
| US8673924B2 (en) | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| EP1569646A2 (en) * | 2002-12-13 | 2005-09-07 | Smithkline Beecham Corporation | Piperidine derivatives as ccr5 antagonists |
| TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| EP1904446A2 (en) * | 2005-07-11 | 2008-04-02 | Ranbaxy Laboratories Limited | Azabicyclo derivatives as muscarinic receptor antagonists |
| JP2009521448A (ja) * | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ |
| WO2007130383A2 (en) | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
| EP1997805A1 (en) * | 2007-06-01 | 2008-12-03 | Commissariat à l'Energie Atomique | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans |
| JP2013028538A (ja) | 2009-11-13 | 2013-02-07 | Dainippon Sumitomo Pharma Co Ltd | 新規アミド誘導体 |
| WO2013076090A1 (en) | 2011-11-25 | 2013-05-30 | Nerviano Medical Sciences S.R.L. | 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors |
| WO2014074517A1 (en) * | 2012-11-08 | 2014-05-15 | Emory University | Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto |
| WO2014079787A1 (en) * | 2012-11-20 | 2014-05-30 | F. Hoffmann-La Roche Ag | Substituted 1,6-naphthyridines |
| MX2015013396A (es) * | 2013-03-18 | 2016-07-08 | Genoscience Pharma | Derivados de quinolinas como nuevos agentes contra el cancer. |
| EP2982666B1 (en) * | 2013-04-04 | 2019-08-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| CN105722835B (zh) * | 2013-09-11 | 2018-07-31 | 癌症研究协会:皇家癌症医院 | 3-芳基-5-取代的-异喹啉-1-酮化合物及它们的疗法应用 |
| MA39763A (fr) * | 2014-03-20 | 2017-01-25 | Samumed Llc | Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci |
| HK1253029A1 (zh) * | 2015-11-06 | 2019-06-06 | Neurocrine Biosciences, Inc. | 作为毒蕈碱性受体4(m4)拮抗剂用於治疗神经系统疾病的n-[2-(1-苄基哌啶-4-基)乙基]-4-(吡嗪-2-基)-哌嗪-1-甲酰胺衍生物及相关化合物 |
-
2016
- 2016-11-04 HK HK18112407.2A patent/HK1253029A1/zh unknown
- 2016-11-04 AU AU2016348524A patent/AU2016348524B2/en not_active Ceased
- 2016-11-04 MX MX2018005215A patent/MX386148B/es unknown
- 2016-11-04 CN CN201680064834.6A patent/CN108349936B/zh active Active
- 2016-11-04 KR KR1020187015620A patent/KR20180073685A/ko not_active Ceased
- 2016-11-04 MA MA043168A patent/MA43168A/fr unknown
- 2016-11-04 MY MYPI2018000570A patent/MY194461A/en unknown
- 2016-11-04 TN TNP/2018/000130A patent/TN2018000130A1/en unknown
- 2016-11-04 BR BR112018008630A patent/BR112018008630A2/pt not_active IP Right Cessation
- 2016-11-04 EP EP16798333.7A patent/EP3371164B1/en active Active
- 2016-11-04 CA CA3001873A patent/CA3001873A1/en not_active Abandoned
- 2016-11-04 WO PCT/US2016/060659 patent/WO2017079641A1/en not_active Ceased
- 2016-11-04 SG SG11201803757UA patent/SG11201803757UA/en unknown
- 2016-11-04 ES ES16798333T patent/ES2915266T3/es active Active
- 2016-11-04 PE PE2018000730A patent/PE20181010A1/es unknown
- 2016-11-04 JP JP2018522553A patent/JP6917989B2/ja active Active
- 2016-11-04 US US15/773,915 patent/US11033539B2/en active Active
-
2018
- 2018-04-23 IL IL258862A patent/IL258862B/en active IP Right Grant
- 2018-05-02 PH PH12018500940A patent/PH12018500940A1/en unknown
- 2018-05-04 CL CL2018001217A patent/CL2018001217A1/es unknown
- 2018-05-04 CO CONC2018/0004800A patent/CO2018004800A2/es unknown
- 2018-05-05 SA SA518391518A patent/SA518391518B1/ar unknown
-
2021
- 2021-01-05 JP JP2021000354A patent/JP2021050243A/ja not_active Withdrawn
- 2021-04-26 US US17/239,726 patent/US20210338653A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021050243A (ja) | 2021-04-01 |
| MX386148B (es) | 2025-03-18 |
| AU2016348524B2 (en) | 2021-01-28 |
| CL2018001217A1 (es) | 2018-08-03 |
| HK1253029A1 (zh) | 2019-06-06 |
| US20180325887A1 (en) | 2018-11-15 |
| SG11201803757UA (en) | 2018-06-28 |
| EP3371164A1 (en) | 2018-09-12 |
| SA518391518B1 (ar) | 2021-06-13 |
| CN108349936B (zh) | 2021-10-01 |
| MY194461A (en) | 2022-11-30 |
| KR20180073685A (ko) | 2018-07-02 |
| PE20181010A1 (es) | 2018-06-26 |
| US11033539B2 (en) | 2021-06-15 |
| CA3001873A1 (en) | 2017-05-11 |
| US20210338653A1 (en) | 2021-11-04 |
| CN108349936A (zh) | 2018-07-31 |
| CO2018004800A2 (es) | 2018-10-31 |
| TN2018000130A1 (en) | 2019-10-04 |
| EP3371164B1 (en) | 2022-03-16 |
| JP6917989B2 (ja) | 2021-08-11 |
| PH12018500940A1 (en) | 2018-12-17 |
| AU2016348524A1 (en) | 2018-05-17 |
| JP2018531981A (ja) | 2018-11-01 |
| MX2018005215A (es) | 2018-08-01 |
| BR112018008630A2 (pt) | 2018-10-30 |
| ES2915266T3 (es) | 2022-06-21 |
| IL258862A (en) | 2018-06-28 |
| MA43168A (fr) | 2018-09-12 |
| WO2017079641A1 (en) | 2017-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258862B (en) | N-[2-(1-Benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperidine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 antagonists for the treatment of neurological diseases | |
| SI3097098T1 (sl) | Postopek za pripravo N-((3-aminooksetana-3-il)metil)-2-(1,1-diokso- 3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina | |
| IL246875A0 (en) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for the treatment of Alzheimer's disease | |
| IL280052A (en) | Preparations containing 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidine-4-yl)methyl)isoindoline-1-one for the treatment of schizophrenia | |
| SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
| NZ725492A (en) | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders | |
| HUE051693T2 (hu) | 5-Klór-N4-[2-(dimetilfoszforil)-fenil]-N2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)-piperidin-1-il] -pirimidin-2,4-diamin kristályos formái | |
| IL291665A (en) | Inhibitors of receptor interaction with protein kinase i for the treatment of disease | |
| IL263188B (en) | Treatment for Parkinson's disease | |
| IL273396A (en) | 4-[[(7-aminopyrazolo[5,1-A]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors | |
| IL263161B (en) | New compounds for the treatment of parasitic diseases | |
| IL255937B (en) | Heterocyclic compounds 3,3-difluoropiperidine carbamate as nr2b nmda receptor antagonists | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| IL249428B (en) | A polymorphic form of n-[2-(6 fluoro-lh-indol-3-yl)ethyl]-3-(2, 2, 3, 3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of Alzheimer's | |
| HK40070316B (zh) | 用於治疗疾病的杂环化合物 | |
| ZA201807944B (en) | Treatment for parkinson's disease | |
| HK40002410A (en) | Inhibitors of beta-arrestin-neurokinin 1 receptor interactions for the treatment of pain | |
| AU2016900635A0 (en) | Inhibitors of beta-arrestin-Neurokinin 1 Receptor Interactions for the Treatment of Pain | |
| TH148816A (th) | อนุพันธ์ฟิวส์เอดแอโซล |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |